Article
A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy - 1 May 2013
Le Gouëllec Audrey, Chauchet Xavier, Laurin David, Aspord Caroline, Verove Julien, Wang Yan, Genestet Charlotte, Trocme Candice, Ahmadi Mitra, Martin Sandrine, Broisat Alexis, Cretin François, Ghezzi Catherine, Polack Benoit, Plumas Joël, Toussaint Bertrand
Abstract excerpt
The industrial development of active immunotherapy based on live-attenuated bacterial vectors has matured. We developed a microsyringe for antigen delivery based on the type III secretion system (T3SS) of P. aeruginosa. We applied the "killed but metabolically active" (KBMA) attenuation strategy to make this bacterial vector suitable for human use. We demonstrate that attenuated P. aeruginosa has the potential to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.